Companies begin to announce their plans for data presentations at ARVO 2024
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations the ARVO annual conference, being held in Seattle, Washington. More companies are expected to announce their presentations in the coming days.
(Image credit: AdobeStock/PRASERT)
The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024, in Seattle, Washington. During this event, pharmaceutical companies plan to have researchers present data regarding their clinical trials and overall progress in therapeutics. With less than 2 weeks to the conference, companies are beginning to share the topics and times for these presentations.
Akari Therapeutics
Akari Therapeutics will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model. Miles Nunn, Akari’s Chief Scientific Officer, will provide an overview during a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT.1
Akari’s long-acting PAS-nomacopan is in the final stages of pre-clinical development as a potential treatment for geographic atrophy (GA).1
Ocuphire Pharma
Ocuphire Pharma, Inc. has shared that Daniel Su, MD will deliver a paper presentation during the Diabetic Retinopathy paper session titled, “Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale on oral APX3330” on Sunday, May 5, 2024 at 4:00 – 4:15 pm PT.2
PharmAbcine
PharmAbcine, Inc. announced that the company's US subsidiary, Wincal Biopharm, Inc. will present preclinical findings on its proprietary Ocular Penetration Carrier (OPC) screening platform, which has shown high potential in treating various ocular diseases using eyedrop formulation of antibody therapeutics, thereby replacing the need for intravitreal injections.3
The presentation titled, “Development of eyedrops for anti-VEGF therapeutic antibodies as a substitute for IVT injection for posterior ocular disease indications” will be held on May 6, 2024 from 3:00 pm to 3:15 pm.3
While these 3 companies are among the first to announce presentations at ARVO 2024, more are expected to share updates. Modern Retina plans to publish a second round of presentation announcements in the coming days as more information becomes available.
References:
